SEROQUEL FDA MedWatch Voluntary U.S. Reports Summary

These tables and charts are created from 2,142 U.S. reports for SEROQUEL (QUETIAPINE FUMARATE) voluntarily reported by individuals directly to the FDA via the MedWatch Reporting System from 2004 through July 30, 2026. Events listed on this page represent serious and often rare adverse events reported to the FDA, and often do not represent typical side effects for the medication. Find common side effects on the most recent official drug label.

For a summary of adverse events including mandatory reports submitted by pharmaceutical companies (all countries and all reporter types) to the FAERS database, View FDA FAERS SEROQUEL Report.

Top Adverse Events Reported with SEROQUEL (from U.S. FDA Medwatch Reports)

	Side Effect	# of FDA Reports
1	DRUG INEFFECTIVE	187
2	NAUSEA	121
3	INSOMNIA	109
4	ANXIETY	107
5	FATIGUE	98
6	DEPRESSION	97
7	DIZZINESS	95
8	SUICIDAL IDEATION	91
9	PRODUCT SUBSTITUTION ISSUE	88
10	WEIGHT INCREASED	86
11	PAIN	85
12	TREATMENT FAILURE	85
13	HEADACHE	81
14	VOMITING	69
15	FEELING ABNORMAL	65
16	DROWSINESS	65
17	TREMOR	63
18	DIARRHEA	62
19	DEATH	60
20	FALL	56
21	CONFUSIONAL STATE	54
22	AGITATION	52
23	SHORTNESS OF BREATH	49
24	GAIT DISTURBANCE	47
25	THERAPY CESSATION	44

Search all MedWatch Reports by Keyword:

SEROQUEL Total Medwatch Safety Reports by Patient Sex

Male	Female	Unknown	Total
680	1179	283	2,142

Medwatch Reporter Type	Count
Consumer	1039
Physician	89
Pharmacist	289
Other Health Professional	259

Top Indications

Product used for unknown indication
Bipolar disorder
Depression
Insomnia
Mental disorder

Type of Outcome Reported
Serious: 1506
Not Serious: 636
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Suspected Role
Primary Suspect: 2142
Concomitant Drugs: 1476
Note: A single MedWatch report can list more than one drug. This summary includes SEROQUEL identified as the suspect drug or as a concomitantly taken drug.

FDA Safety-Related Labeling Changes

SEROQUEL (QUETIAPINE FUMARATE) Rx Drug:
FDA Safety-related Labeling Changes

Have experience (good or bad) with SEROQUEL? Rate SEROQUEL at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

NOTES

This report, created by AskaPatient.com, is derived from U.S. drug-related adverse event cases that were reported directly to the FDA using the voluntary MedWatch online or paper reporting system. MedWatch is the voluntary FDA system for consumers, physicians, and others to directly report adverse reactions. The Medwatch initiative was launched in 1993 as a voluntary reporting program for consumers, physicians and other healthcare practitioners.

After processing the received forms, the FDA adds the MedWatch reports to the FDA Adverse Events Reporting System(or FAERS database.) Click here for the complete FAERS report summary, which includes mandatory reports submitted by pharmaceutical companies (worldwide) combined with the MedWatch reports. MedWatch Reports only represent about 5% of the FAERS database. For more, read "Does the FDA's Rapidly Growing Database of Adverse Events Improve Drug Safety?"

The data in this report was obtained from Open FDA. Data was last updated to include reports through January 27, 2026. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event.

Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on Open FDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions about this report.